Navigation Links
Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
Date:12/20/2013

IRVINE, CA (PRWEB) December 20, 2013

Proove Biosciences, the leader in providing personalized genetic pain medicine services, participated and presented clinical data and research at the Eastern Pain Association’s Annual Meeting on December 7, 2013. The meeting covered current topics in pain medicine and opioid treatment, and took place at the New York Marriott Downtown, in Manhattan.

The EPA offers local and regional scientific meetings to foster an exchange of clinical and scientific information among multidisciplinary health professionals and researchers interested in the field of pain. The Annual EPA Scientific Meeting offered symposia and lectures given by nationally recognized speakers, posters and exhibits designed to appeal to a wide spectrum of specialists and interests.

The EPA’s Annual Meeting concluded a successful and busy year for Proove presenting research throughout the country. Most recently, Proove presented data and findings at the ASRA’s Pain Medicine Meeting, The National Workers Compensation Conference and Expo, and the Common Sense Pain Management Conference.

“Our research and clinical team, along with our aggressive business development efforts have allowed Proove to experience outstanding growth throughout the year,” stated Proove Biosciences President and Founder,Brian Meshkin. “We are the only company providing proprietary testing services in personalized pain medicine. We are happy to have been a part of the EPA’s regional meeting, and exhibiting our work with physicians, psychologists, nurses, and scientists dedicated to pain research.”

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2013/12/prweb11440349.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
2. Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
3. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
4. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
5. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
6. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
7. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
8. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
9. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
10. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... of cannabis testing technology at the Spring 2016 Marijuana Business Conference and Expo. ... pesticides, residual solvents, heavy metals, and more. Expo attendees can stop by booth ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... mobile devices with fingerprint recognition for secure access, voice recognition for hands-free communication, ... ways consumers are interacting with biometrics technology today. But if they asked ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April 27, ... ) announced today that Martine Rothblatt , Ph.D., ... provide an overview and update on the company,s business ... Care Conference. The presentation will take place ... Time, and can be accessed via a live webcast ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... Clark has joined the company as an Expert Consultant. Mr. Clark was ... collaborations and managing the development of small molecule monographs based on analytical methods. ...
Breaking Biology Technology:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/15/2016)... 2016 Yissum Research Development Company of ... of the Hebrew University, announced today the formation of ... of various human biological indicators. Neteera Technologies has completed ... private investors. ... of electromagnetic emissions from sweat ducts, enables reliable and ...
(Date:3/11/2016)... , March 11, 2016 ... market research report "Image Recognition Market by Technology (Pattern ... and Advertising), by Deployment Type (On-Premises and Cloud), by ... 2022", published by MarketsandMarkets, the global market is expected ... USD 29.98 Billion by 2020, at a CAGR of ...
Breaking Biology News(10 mins):